The Preventive Value and Potential Mechanisms of Zinc Finger DHHC-Type Containing 7 (ZDHHC7) for Hypertension Based on Pharmacogenomic Mediation Analysis
Clicks: 1
ID: 317502
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #51 of 62 articles by views in American Journal of Hypertension
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objective To investigate the specific mechanisms by which zinc finger DHHC-type containing 7 (ZDHHC7) regulates immune cells and plasma metabolites to reduce the risk of hypertension. Methods Expression quantitative trait loci (eQTL) data for ZDHHC7 were obtained from the eQTLGen database (n = 26,118), while genome-wide association studies (GWAS) data for hypertension (n = 484,598), immune cells (n = 3658), and plasma metabolites (n = 8192) were extracted from the GWAS Catalog. All datasets were derived from European populations. Five Mendelian randomization (MR) methods, including inverse variance weighted (IVW), MR-Egger, weighted median, simple mode, and weighted mode, were used to evaluate causal relationships. Sensitivity analyses were performed using Cochran’s Q test, MR-Egger intercept, leave-one-out analysis, and MR-PRESSO. Statistical power of the MR analysis was assessed via post hoc power calculation. Two-step MR was conducted to evaluate the mediating effects of immune cells and plasma metabolites on the relationship between ZDHHC7 and hypertension risk. Results All 5 MR methods indicated a negative association between ZDHHC7 and hypertension risk (IVW: OR = 0.995, 95% CI, 0.992-0.998, P <.001; MR-Egger: OR = 0.994, 95% CI, 0.989-0.998, P = .014; weighted median: OR = 0.994, 95% CI, 0.991-0.998, P = .004; simple mode: OR = 0.993, 95% CI, 0.987-1.000, P = .049; weighted mode: OR = 0.994, 95% CI, 0.990-0.997, P <.001). The summary-level Mendelian randomization (SMR) analysis yielded consistent results (OR = 0.995, 95% CI, 0.990-0.998, P = .011). Sensitivity analyses showed no significant heterogeneity or bias. The estimated post hoc power was 23.73%. Mediation analysis further revealed that 3 immune cell phenotypes (the proportion of B cell subsets lacking IgD and CD27 markers, expression of CD123 on plasmacytoid dendritic cells, and expression of CD123 on CD62L+ plasmacytoid dendritic cells) and 3 plasma metabolites (1-stearoylphosphatidylinositol, nicotinic acid, and lactate) mediated the relationship between ZDHHC7 and hypertension risk. Conclusion ZDHHC7 may reduce the risk of hypertension by modulating specific immune cells and plasma metabolites.
| Reference Key |
openalex_W7164909405
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Lu Meijuan, Junchi Guo, M Zhang, Zhao Yingqiang, Xu Qiang |
| Journal | American Journal of Hypertension |
| Year | 2026 |
| DOI |
10.1093/ajh/hpaf210
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.